MoonLake Immunotherapeutics (NASDAQ:MLTX) vs. MorphoSys (NASDAQ:MOR) Head-To-Head Comparison

MoonLake Immunotherapeutics (NASDAQ:MLTXGet Rating) and MorphoSys (NASDAQ:MORGet Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.

Institutional and Insider Ownership

76.1% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 2.1% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares MoonLake Immunotherapeutics and MorphoSys’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MoonLake Immunotherapeutics N/A N/A -$4.54 million N/A N/A
MorphoSys $212.49 million 2.97 -$608.66 million ($7.05) -0.65

MoonLake Immunotherapeutics has higher earnings, but lower revenue than MorphoSys.

Risk and Volatility

MoonLake Immunotherapeutics has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for MoonLake Immunotherapeutics and MorphoSys, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoonLake Immunotherapeutics 0 0 6 0 3.00
MorphoSys 5 1 2 0 1.63

MoonLake Immunotherapeutics currently has a consensus target price of $20.33, indicating a potential upside of 78.52%. MorphoSys has a consensus target price of $17.58, indicating a potential upside of 281.34%. Given MorphoSys’ higher probable upside, analysts clearly believe MorphoSys is more favorable than MoonLake Immunotherapeutics.

Profitability

This table compares MoonLake Immunotherapeutics and MorphoSys’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MoonLake Immunotherapeutics N/A 19.69% 7.17%
MorphoSys -357.89% -1,157.24% -34.01%

Summary

MoonLake Immunotherapeutics beats MorphoSys on 8 of the 11 factors compared between the two stocks.

About MoonLake Immunotherapeutics

(Get Rating)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

About MorphoSys

(Get Rating)

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.